PADCEV (enfortumab vedotin-ejfv) is a prescription medication used in the treatment of adult patients with certain types of bladder cancer, specifically urothelial carcinoma, that has spread (metastasized) or cannot be removed by surgery (locally advanced) and who have previously received other cancer treatments. PADCEV is a type of drug known as an antibody-drug conjugate (ADC), which combines an antibody that targets cancer cells with a chemotherapy drug, allowing for direct delivery of the cancer-killing agent to the tumor cells. This targeted approach helps to minimize damage to normal, healthy cells. PADCEV works by targeting Nectin-4, a protein found on the surface of some cancer cells, and then releasing a toxic agent to kill these cells. It is administered through intravenous infusion and has shown significant efficacy in improving survival rates and reducing tumor size in eligible patients. However, it can also cause serious side effects, and its use must be carefully monitored by a healthcare professional.